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Background: The purpose of this study was to evaluate the effects of intravenous zoledronic acid applied systemically 
on osseointegration of dental implants and the surrounding bone mineral density (BMD) in the ovariectomized rats.
Material and Methods: 36 rats were divided into three groups: control (CTRL), ovariectomy (OVX), and ovariec-
tomy-zoledronic acid (OVX/ZOL). The rats in the CTRL group underwent sham surgery, while rats in OVX and 
OVX / ZOL group underwent ovariectomy. After 12 weeks, rats from OVX / ZOL were injected with 0.04 mg/
kg ZOL intravenously once a week for 6 weeks. The rats from CTRL and OVX groups were injected with 0.9% 
NaCl.  Implants were placed in the left tibia. After 8 weeks, rats were sacrificed and tibia bones were removed for 
radiodensitometric examination. Digital radiographs of bones’ lateral surface were taken. The BMD was mea-
sured by using radiographic analysis software. 
Results: Statistically significant differences were found between all groups (p<0.05). While highest mean BMD 
values were observed in the CTRL group, the lowest were in the OVX group. 
Conclusions: The systemic use of ZOL has increased the bone density around the implants inserted osteoporotic 
rat tibia.




Skeletal diseases such as osteoporosis that affect the 
bone metabolism cause alveolar bone resorption and 
may lead to difficulties in the application of dental im-
plants. Osteoporosis is an osteometabolic disease that 
occurs in postmenopausal women due to decrease of 
estrogen levels (1). This disease is characterized by de-
crease in the bone density, strength, and regenerative 
capacity as well as deterioration of microstructure. As 
a result, osteoporosis is considered to be a relative con-
traindication for dental implant applications (2).
Many studies have investigated the role of osteoporosis 
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in dental implant healing. Medications used for osteo-
porosis have been reported to be effective in preventing 
bone loss around the inserted implant (3,4). Bisphos-
phonates (BP) are the most commonly preferred drugs 
in the treatment of osteoporosis. BP is a pyrophosphate 
analog that contains phosphate-carbon-phosphate bond 
and remains stable even when exposed to chemical and 
enzymatic hydrolysis. It reduces the fracture risk by in-
creasing bone mineral density, reducing bone turnover 
and preventing bone resorption of osteoclasts (5). The 
mechanism of action of this drug is by inhibition of os-
teoclastic bone resorption via formation of strong bonds 
between hydroxyapatite crystals and BP (6).
Oral BPs are often preferred for the treatment of osteopo-
rosis. However, there are dangerous side effects of long-
term, low therapeutic dose BP treatments. Bisphospho-
nate-related osteonecrosis of the jaw (BRONJ) has been 
reported as a side effect of BP use. In the treatment of 
multiple myeloma and metastatic bone disease, the dose 
of intravenous BP, duration of use, method of application, 
and the time of dental surgery should be adjusted with con-
sideration of a risk of development of BRONJ. Prior to the 
implant surgery each patient receiving a BP therapy should 
be informed about the risks of developing BRONJ (7).
Previous studies have reported that BPs increase bone 
density around the implant. Giro et al. (2) have studied 
the effect of alendronate treatment for estrogen deficien-
cy on the bone density around the implant. They reported 
that the bone density around the implant was significantly 
higher in the group that used alendronate. Viera-Negron 
et al. (8) investigated the effect of alendronate on bone 
density around the implant and implant osseointegration 
and reported that in the alendronate group, the bone den-
sity surrounding the implants was significantly higher. In 
another study, Yıldız et al. (9) studied the effects of zole-
dronic acid on implants osseointegration and bone den-
sity around the implant and found that zoledronic acid 
was associated with the increased bone density. Previous 
studies have shown that implants were pertinent in osteo-
porosis animal models treated with BP.
Zoledronic acid (ZOL) is a new generation bisphos-
phonate that shows a high affinity to hydroxyapatite. It 
accumulates for a very long time in the bone mineral 
structure therefore, it is the most powerful drug in the 
BP group. Recent animal studies have investigated the 
effect of short-term or single subcutaneous and intrave-
nous ZOL administration on bone density around the 
implant (10-12). However, the studies that look into the 
effects of long-term intravenous ZOL administration on 
bone density around the implant are limited.
Histograms are utilized in the evaluation of bone healing 
by using digital radiographs. High histogram value of the 
area under the examination means that the radiograph in 
that area has higher opacity. Along the same lines, when 
comparing bone densities of different samples in digital 
radiographs, measuring the histogram values gives us an 
idea about the changes in the bone density in that area 
(13). The purpose of this study was to evaluate the effect 
of long-term, systemic administration of ZOL on bone 
density around the implant in an osteoporosis rat model 
by using radiodensitometric analysis.
Material and Methods
- The Study Design 
This study was conducted with a total of 36 16-week-old 
female Wistar rats that were housed in ambient condi-
tions with 12-hour periods of dark and light cycles. Ani-
mals were fed with standard feed, food and water were 
not limited. The study was conducted with the permis-
sion of the Gulhane Military Medical Academy Animal 
Ethics Committee.
Animals were randomly divided into three groups (12 
animals in each group): control (CTRL), ovariectomy 
(OVX) and ovariectomy + ZOL (OVX / ZOL). Follow-
ing a 7-day acclimatization period the rats from the 
OVX and OVX / ZOL groups underwent an operation 
for bilateral ovariectomy. Before the ovariectomy pro-
cedure, animals received a single dose of intraperito-
neal injection of 0.35 mg/kg Ketamine HCl and 0.5 mg/
kg Xylazine to achieve anesthesia. The CTRL group 
underwent sham surgery. During this sham surgery, 
the abdomen was opened in the same way, ovaries were 
dissected and their anatomical position was examined, 
then the abdomen was closed without removing the ova-
ries. Twelve weeks after the surgery, rats from the OVX 
/ ZOL group were administered a single dose of 0.04 
mg / kg ZOL from the tail vein every week for 6 weeks. 
Meanwhile, rats from the CTRL and OVX groups re-
ceived the same dose of 0.9% NaCl through the tail vein 
for the same amount of time. 
After completion of all intravenous drug injections, 
animals were anesthetized by intramuscular injection of 
0.35 mg / kg Ketamine HCl and 0.5 mg / kg Xylazine. 
Rats’ legs were shaved, washed and wiped with antisep-
tic iodine solution. A 20 mm incision was made on the 
medial of the left tibia’s proximal metaphyseal. After the 
procedure, the dissecting bone was removed. The bed 
for the bicortical implant was prepared by using a drill 
physiodispenser under sterile saline irrigation. The spe-
cially crafted, sandblasted titanium micro-implants with 
acid-etched surfaces that mimics the surface properties 
of the implants used in humans were utilized (Fig. 1). The 
micro-implants [4 mm in length and 1.6 mm in diame-
ter] were placed in the prepared implant bed. After the 
implantation, fascia and skin were closed with a suture 
that can be resorbed in separate layers. Post-operatively 
the animals received a single dose of intramuscular in-
jection of 1 mg / kg Tramadol hydrochloride and 50 mg 
/ kg Cefazolin sodium. An 8-week bone healing period 
was given in order to ensure osseointegration (14). After 
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this period, animals were sacrificed by intravenous injec-
tion of 100 mg / kg Sodium pentobarbital. Tibia bones 
that had implants were removed by en-bloc resection and 
were prepared for radiological examinations.
- Radiodensitometric analysis
The digital radiographs of tibia samples were taken 
with the standard test set, all from the same distance 
and with the same kilovolts, milliampers and exposure 
time (RVG, Trophy Radiologie, Vincennes, France). 
The sample was placed on the digital radiography sen-
sors and an X-ray was taken perpendicularly from 20 
cm above the sensor’s surface (New Life Best-X DC, 
Torino, Italy). The X-ray parameters were adjusted to 
65 KVP, 300 mA and 0.16 ms exposure time. The reso-
lution of digital images was set to 635 ppi (pixels per 
inch), the size was set to 900 x 641 dpi (dots per inch) 
and pixel size was set to 40 µm. The resulting digital 
images were saved in JPEG (Joint Photographic Experts 
Group) format.
Bone mineral density (BMD) measurements were per-
formed by a standard computer (Intel Core i5, 2.5 GHz 
processor, Intel Corp., Santa Clara, CA, USA), with the 
OS X Yosemite (Apple, Copertino, CA, USA) operat-
ing system and 13.3 inch LED backlit flat screen (Mac 
Book Pro, Apple, Copertino, CA, USA) by using Image 
J 1.33 image analysis software (National Institutes of 
Health, Bethesda, MD, USA). Sampling was done from 
areas of equal width that were selected from the medul-
lary bone areas that were adjacent to implant’s apical 3 
grooves. The software’s histogram property, which ex-
presses the light distribution of the digital image in one 
graph, was used to obtain the mean BMD values of each 
sample (Fig. 2).





Median Minimum Maximum p
CTRL 94.20 (2.27) (11) 94.79 90.36 97.68
p<0.05OVX 55.79 (2.33) (11) 55.77 51.59 59.32
OVX-ZOL 74.62 (2.43) (11) 73.59 71.44 79.64
Table 1. Comparison of mean BMD percentage values along with SDs of the groups as determined 
by radio-densitometric analysis.
Fig. 1. Custom made titanium micro-implant and screw.
- Statistical Analysis 
The Kolmogorov-Smirnov test was used to assess 
whether the variables were normally distributed. The 
Kruskal-Wallis test was used for comparisons between 
the three groups in statistical evaluation of resulting 
BMD values. The pair-wise comparison between the 
groups was made by Bonferroni corrected Mann-Whit-
ney U test. p <0.05 was considered statistically signifi-
cant.
Results
All procedures were well tolerated by animals. One 
sample from each group was excluded from the ra-
diodensitometric analysis. The means and standard 
deviation for BMD values are given in table 1. There 
were significant differences between the three groups 
in the comparison of BMD values (p <0.05). The high-
est mean BMD value was detected in the CTRL group 
with 94.20 ± 2.27, which was followed by OVX / ZOL 
Bone mineral density (BMD), control group (CTRL), ovariectomy group(OVX), and ovariec- tomy-
zoledronic acid group (OVX/ZOL).
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Fig. 3. Differences in BMD parameters between CTRL, OVX/
ZOL, and OVX groups. Bone mineral density (BMD), control 
group (CTRL), ovariectomy group(OVX), and ovariec- tomy-zole-
dronic acid group (OVX/ZOL).
group with 74.62 ± 2.43 and OVX group with 55.79 ± 
2.33. The pair-wise comparisons showed that there were 
significant differences between CTRL and OVX groups 
(p <0.05) and between CTRL and OVX / ZOL groups 
(p <0.05) in terms of BMD values. These results show 
that BMD values decreased significantly in OVX group 
compared to the CTRL group. Moreover, the BMD va-
lues in the OVX / ZOL group were significantly higher 
compared to those of the OVX group (Fig. 3).
Discussion
The results of this study suggested that estrogen defi-
ciency negatively impacts bone-implant osseointegra-
tion. The radiographic analysis of bone density showed 
that the bone density of the OVX group was significant-
ly lower than those of CTRL and OVX / ZOL groups 
(p<0.05). The ovariectomy procedure applied to the 
OVX group and findings related to the decreased bone 
density are similar to studies conducted by Sakakura 
et al. (15) and Giro et al. (2). Moreover, administration 
of ZOL positively affected the bone density around the 
implant in the OVX / ZOL group.
Osteoporosis is a systemic skeletal disease that leads to 
increased bone fragility and is characterized by changes 
in the microstructure and decrease in bone mass. Many 
studies have reported the loss of implants to be associ-
ated with the decline in patient’s medical condition. The 
imbalance between bone formation and degradation is 
observed earlier in the osteoporotic jawbone compared 
to long bones, as the alveolar bone is regenerated at a 
much faster rate. The high turnover percentage of the 
alveolar bone helps the mechanical durability of the 
maxilla and mandible, but small oral surgeries reduces 
local bone turnover (16). The preventive effects of os-
teoporosis on osseointegration of the implant, as well as 
causing the deficiency in the connective tissue adjacent 
to the implant leading to bone loss, has been reported in 
many studies (17-19).
The results of our study that suggested beneficial effect 
of intravenous BP on early bone fixation of dental im-
plants was also highlighted in many other studies. New 
findings support the notion that BPs such as ibandronate, 
pamidronate and ZOL facilitate implant-bone fixation 
on healthy bone and prevent the implant loss (6).
Narai and Nagatha (4) have determined that integrated 
implant’s rotation torque was increased significantly in 
alendronate-treated ovariectomized rats compared to 
the healthy control group. In addition, another study 
has reported that osseointegration was increased in rats 
treated with ibandronate, however, there was no signifi-
cant relationship between the degree of osseointegra-
tion and high-dose ibandronate (17).
Currently, ZOL is the most potent intravenous BP used 
and was approved by the Food and Drug Administra-
tion (FDA) in 2001 (20). The therapeutic use of ZOL has 
two preventive effects on osteoporosis: decreases bone 
resorption and supports bone anabolism. Furthermore, 
compared to the control group, ZOL has been shown 
to lead to two-fold increase in the bone growth around 
the implant (21). In this sense, in our study we benefited 
from systemically administered ZOL in terms of im-
proving the osseointegration of titanium implants in 
ovariectomized rats.
There are various animal studies that investigated the 
treatment duration and dosage of ZOL. Lespessailles et 
al. (22) have determined that a single dose of intrave-
nous 20 mg / kg ZOL lead to an increase in bone density 
in the ovariectomized rat model. Yıldız et al.(9) admin-
istered a single 0.1 mg / kg intravenous dose of ZOL 
to ovariectomized rabbits and 8 weeks later observed a 
significant improvement in bone mineralization around 
titanium dental implants. However, Brouwers et al. (23) 
have administered the same dose as the previous study 
to rats and 12 weeks later observed a significant de-
crease in bone density of the proximal tibia. According 
to the information given in this and other studies, the 
current protocol for intravenous administration of BP 
should be given in monthly doses to maintain therapeu-
tic drug levels and to facilitate patient compliance (8). 
In our study, 12 weeks after the ovariectomy procedure, 
rats from the OVX / ZOL group were administered a 
single dose of 0.04 mg / kg ZOL per week for 6 weeks. 
This dose was chosen to simulate the cumulative dose 
of ZOL given to humans in clinical practice.
Many methods are used to evaluate the condition of the 
bone around the implant. Radiodensitometric analy-
sis is preferred in clinical evaluation for being a rapid, 
non-invasive test at a low cost. In this study, the bone 
density image obtained from the specific area around 
the implant by using the histogram method was evalu-
ated by using dedicated image analysis software. This 
method gave similar results in many histological studies 
(24,25).
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In addition to inhibitory effects on osteoclasts, BP’s an-
abolic effects have also been highlighted in many stud-
ies. In another study, it was reported that in humans, 
ZOL inhibits osteoclast maturation and differentiation 
by directly affecting the osteoclasts (26). Therefore, 
these studies have linked the beneficial effects of BPs 
on bone density in part, to their direct effects on os-
teoblasts. In our study, the positive effect of ZOL on 
the implant osseointegration and bone structure can be 
explained by the anti-osteoclastic and anabolic action 
of ZOL.
In this study, ZOL injections began 12 weeks after the 
ovariectomy procedure. The implants were placed on 
18th week and radiodensitometric evaluations were con-
ducted starting from 26th week. Pan et al. (27) reported 
that after the ovariectomy, the earliest time they observed 
significant changes in the bone around the implant in the 
rat tibia was at the 12-24th week. In their radiodensito-
metric studies, Sakakura et al. (15) measured the amount 
of cancellous bone around the implant, which was placed 
in the rat’s tibia, 12 weeks after the ovariectomy proce-
dure and determined that bone density values were sig-
nificantly lower in ovariectomized rats.
Animals such as rabbits, pigs, dogs and rats are fre-
quently used in osteoporosis studies. In our study, rat 
model was used because they are easy to breed, inex-
pensive, easier to manipulate compared to larger ani-
mals, provide the ability to obtain more samples, are 
resistant to infections, and because there are many re-
sources available about their physiology.
According to our results, systemic administration of 
ZOL has increased the implant osseointegration in the 
rat model with suppressed estrogen. In addition, our 
radiodensitometric analyses showed that ovariectomy-
related estrogen deficiency might jeopardize the bone 
structure. When examined in detail, the OVX group had 
decreased cortical bone thickness, decreased new bone 
formation, increased bone porosity, and limited bone-
implant contact compared to other groups. However, 
although intravenous administration of ZOL increased 
the osteoporotic bone regeneration around the implant 
in OVX / ZOL group, the mean bone density values of 
this group were still lower than non-osteoporotic CTRL 
group.
Despite these results, implant losses can occur after 
dental implant surgery in some patients treated with in-
travenous BP. This can be explained by the increased 
risk of BRONJ after the surgery in patients that receive 
BP. As reported in many studies, oncological patients 
using intravenous BP face the risk for developing 
BRONJ after the dental procedures due to introduction 
of other factors such as diabetes, corticosteroid therapy, 
alcohol and tobacco use, and poor oral hygiene (28). It 
is still unclear whether the BP therapy should or should 
not be terminated prior to surgical procedures in or-
der to decrease the likelihood of BRONJ development 
(29). However, it has been reported that BP dosages 
used in the treatment of osteoporosis in patients who 
did not undergo surgical procedures pose lower risk for 
developing BRONJ (30). The dental health community 
should understand the effects of BPs on dental implant 
surgeries in patients receiving intravenous BP treat-
ment. Our study is interesting in terms of evaluating the 
therapeutic strategies in patients with dental implants; 
however, high bone turnover values in ovariectomized 
rats cannot be translated directly to the osseointegration 
process in post-menopausal human. New clinical stud-
ies are needed to better examine the long-term effects of 
BPs on dental implant osseointegration.
Conclusions
Despite the limitations of this animal study, our ra-
diodensitometric results showed that in osteoporotic rats 
treated with the same dosage of ZOL as used in humans, 
the bone densitometry values were higher compared to 
the group that did not receive the drug.
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